Know Cancer

or
forgot password

Observational Study Assessing Molecular Features Predicting Response/Resistance to Trastuzumab in Metastatic Breast Cancer Patients


N/A
18 Years
N/A
Not Enrolling
Female
Breast Cancer

Thank you

Trial Information

Observational Study Assessing Molecular Features Predicting Response/Resistance to Trastuzumab in Metastatic Breast Cancer Patients


Inclusion Criteria:



- Hystological diagnosis of breast cancer

- Availability of tumor tissue

- Availability to assess the response to Trastuzumab according to RECIST criteria

- Availability of clinical data

Exclusion Criteria:

- Unavailability of tumor tissue

- Impossibility to assess the response to Trastuzumab according to RECIST criteria

Type of Study:

Observational

Study Design:

Observational Model: Cohort, Time Perspective: Retrospective

Outcome Measure:

Association of a specific biomarker with response to Herceptin-based therapy

Outcome Time Frame:

Response after two months of treatment

Safety Issue:

No

Principal Investigator

Armando Santoro, MD

Investigator Role:

Principal Investigator

Investigator Affiliation:

Istituto Clinico Humanitas

Authority:

Italy: Ministry of Health

Study ID:

ONC/OSS-01/2007

NCT ID:

NCT00740532

Start Date:

October 2007

Completion Date:

August 2010

Related Keywords:

  • Breast Cancer
  • EGFR, HER-2, HER-3, MET, KRAS
  • Breast Neoplasms

Name

Location